Financial Results
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Revenue from operations surged about 69% year-on-year to ₹5,007 lakhs in FY25, up from ₹2,968 lakhs in FY24, helped by a new 'Energy' segment that contributed ₹1,142 lakhs versus zero a year earlier. Net profit rose roughly 67% to ₹290.4 lakhs (from ₹173.6 lakhs), and EPS climbed to ₹4.51 from ₹2.70. The Ayurveda segment, the core business, grew more modestly at about 30% to ₹3,865 lakhs. However, the quality of earnings weakened: EBITDA margin compressed to around 10.4% from 15.1% as the new segment carries thinner margins, and operating cash flow collapsed to just ₹6.6 lakhs from ₹269.5 lakhs due to a sharp build-up in trade receivables. Short-term borrowings also jumped to ₹741 lakhs from ₹124 lakhs, raising leverage. The statutory auditor issued an unmodified (clean) opinion.
Headline profit and revenue growth is impressive, but rising receivables, weak cash generation, and a surge in short-term debt are red flags that could pressure the stock if working capital does not normalise. Investors should watch for improvement in cash collection and debt levels in coming quarters.